| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003770227 |
| P356 | DOI | 10.1038/SREP40523 |
| P932 | PMC publication ID | 5238375 |
| P698 | PubMed publication ID | 28091615 |
| P2093 | author name string | Chunmei Li | |
| Jie He | |||
| Jianping Wang | |||
| Le Kang | |||
| Jingwei Tian | |||
| Yonglin Gao | |||
| Rui Han | |||
| Yanshen Li | |||
| P2860 | cites work | Angiotensin II regulates ACE and ACE2 in neurons through p38 mitogen-activated protein kinase and extracellular signal-regulated kinase 1/2 signaling | Q28592286 |
| Renoprotective properties of pirfenidone in subtotally nephrectomized rats | Q34087790 | ||
| Activation of liver X receptor improves viability of adipose-derived mesenchymal stem cells to attenuate myocardial ischemia injury through TLR4/NF-κB and Keap-1/Nrf-2 signaling pathways | Q34579503 | ||
| p38 mitogen-activated protein kinase and liver X receptor-α mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells | Q35718937 | ||
| Improving vagal activity ameliorates cardiac fibrosis induced by angiotensin II: in vivo and in vitro | Q36310106 | ||
| Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy | Q36392895 | ||
| Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. | Q36579769 | ||
| Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis | Q37101896 | ||
| Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches | Q37175653 | ||
| Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis. | Q51539353 | ||
| Involvement of angiotensin II and reactive oxygen species in pancreatic fibrosis. | Q53288278 | ||
| The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects. | Q53615353 | ||
| Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts. | Q54266973 | ||
| Long-term oral Asperosaponin VI attenuates cardiac dysfunction, myocardial fibrosis in a rat model of chronic myocardial infarction | Q83462639 | ||
| Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease | Q87521640 | ||
| Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases | Q38049919 | ||
| Angiotensin-(1-7): beyond the cardio-renal actions. | Q38068237 | ||
| Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus | Q38238448 | ||
| Losartan: Comprehensive Profile. | Q38519556 | ||
| ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis | Q38781834 | ||
| The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice | Q39745759 | ||
| Increased mortality and aggravation of heart failure in liver X receptor-α knockout mice after myocardial infarction | Q40986115 | ||
| GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats | Q41586886 | ||
| Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. | Q41666649 | ||
| Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization | Q42583421 | ||
| Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells | Q42628650 | ||
| Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. | Q42706428 | ||
| Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats | Q43162268 | ||
| Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system | Q43177134 | ||
| Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages | Q45207632 | ||
| Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. | Q46493539 | ||
| Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology | Q46771630 | ||
| Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction | Q47399226 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 40523 | |
| P577 | publication date | 2017-01-16 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Pirfenidone controls the feedback loop of the AT1R/p38 MAPK/renin-angiotensin system axis by regulating liver X receptor-α in myocardial infarction-induced cardiac fibrosis | |
| P478 | volume | 7 |
| Q42316580 | CO-releasing molecules CORM2 attenuates angiotensin II-induced human aortic smooth muscle cell migration through inhibition of ROS/IL-6 generation and matrix metalloproteinases-9 expression |
| Q92548798 | Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis |
| Q92977808 | Danqi soft capsule prevents infarct border zone remodelling and reduces susceptibility to ventricular arrhythmias in post-myocardial infarction rats |
| Q60956756 | Long-Term Regulation of Excitation-Contraction Coupling and Oxidative Stress in Cardiac Myocytes by Pirfenidone |
| Q54937508 | MiR-33 promotes myocardial fibrosis by inhibiting MMP16 and stimulating p38 MAPK signaling. |
| Q89014006 | Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury |
| Q51745535 | Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro. |
| Q64235758 | Transcriptome network analysis identifies protective role of the LXR/SREBP-1c axis in murine pulmonary fibrosis |
Search more.